Sareum Holdings Plc

  • Market Cap: N/A
  • Industry: Miscellaneous
  • ISIN: GB00BMC3RJ87
GBP
0.12
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Miscellaneous

stock-summary
Market cap

GBP 17 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.56

stock-summary
Return on Equity

-194.91%

stock-summary
Price to Book

7.58

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-43.18%
0%
-43.18%
6 Months
-12.28%
0%
-12.28%
1 Year
-53.7%
0%
-53.7%
2 Years
-80.0%
0%
-80.0%
3 Years
-85.71%
0%
-85.71%
4 Years
-95.69%
0%
-95.69%
5 Years
-81.75%
0%
-81.75%

Sareum Holdings Plc for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-1.02%
EBIT Growth (5y)
-201.94%
EBIT to Interest (avg)
-2.94
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.96
Sales to Capital Employed (avg)
0.03
Tax Ratio
22.55%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
8.02
EV to EBIT
-8.97
EV to EBITDA
-8.97
EV to Capital Employed
30.56
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-340.60%
ROE (Latest)
-47.85%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Sareum Holdings Plc"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2023 is 0.00% vs 0.00% in Jun 2022",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2023 is -45.45% vs -46.67% in Jun 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'23",
        "Jun'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.00",
          "val2": "-2.60",
          "chgp": "-53.85%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.20",
          "val2": "-2.20",
          "chgp": "-45.45%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Jun'23stock-summary
Jun'23
Jun'22
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-4.00
-2.60
-53.85%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-3.20
-2.20
-45.45%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales

YoY Growth in year ended Jun 2023 is 0.00% vs 0.00% in Jun 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Jun 2023 is -45.45% vs -46.67% in Jun 2022

stock-summaryCompany CV
About Sareum Holdings Plc stock-summary
stock-summary
Sareum Holdings Plc
Miscellaneous
Sareum Holdings plc is engaged in the discovery and development of new therapeutic drugs by a combination of skills in biology, computational chemistry and medicinal chemistry. The Company's drug programs include Checkpoint Kinase 1 (CHK1), Aurora+FLT3 Kinase and Tyrosine Kinase 2- autoimmune diseases (TYK2), Aurora+FLT3 kinase and TYK2 kinase-cancer. Its Chk1 program is the advanced program and shows potency in disease models of lung and colon cancers in combination with chemotherapy; acute myeloid leukemia (AML) and B-cell lymphoma, and head and neck cancers in combination with radiotherapy. TYK2 kinase program focuses on developing a series of TYK2 inhibitors that can be dosed orally against various autoimmune and inflammatory disorders, including psoriasis and rheumatoid arthritis. Its Aurora+FLT3 Kinase program focuses on AML and other blood cancers. Its TYK2 kinase prevents T-cell acute lymphoblastic leukemia (T-ALL) cells from proliferating by causing programmed cell death.
Company Coordinates stock-summary
Company Details
Unit 2A, Langford Arch, London Road, Pampisford CAMBRIDGE None : CB22 3FX
stock-summary
Tel: 44 1223 497700
stock-summary
Registrar Details